Promis Neuroscie Financials
This page shows Promis Neuroscie (PMN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ProMIS is operating like a cash-funded research platform, with development spending rather than commercial revenue driving the balance sheet.
Across recent annual filings, financing inflows of$66.6M roughly matched cumulative operating cash burn of$66.1M , which means the business has effectively been sustained by new capital rather than internally generated cash.
The latest deterioration came mainly from R&D intensity: research spending jumped to
The one year of positive net income at
Financial Health Signals
Promis Neuroscie does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Promis Neuroscie passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Promis Neuroscie reported a net loss of $39.7M while operations used $28.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Promis Neuroscie reported -$39.7M in net income in fiscal year 2025. This represents a decrease of 1529.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Promis Neuroscie held $6.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Promis Neuroscie invested $33.4M in research and development in fiscal year 2025. This represents an increase of 213.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
PMN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $33.4M+213.8% | $10.6M+34.9% | $7.9M-51.0% | $16.1M+247.7% | $4.6M |
| SG&A Expenses | N/A | $6.8M+9.7% | $6.2M-3.0% | $6.4M-12.5% | $7.3M+99.1% | $3.7M |
| Operating Income | N/A | -$40.2M-138.7% | -$16.8M-18.0% | -$14.3M+39.0% | -$23.4M-182.0% | -$8.3M |
| Interest Expense | N/A | N/A | N/A | N/A | $282K-32.2% | $416K |
| Income Tax | N/A | N/A | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$39.7M-1529.3% | $2.8M+121.0% | -$13.2M+26.9% | -$18.1M-84.5% | -$9.8M |
| EPS (Diluted) | — | -$22.61 | $2.63 | -$1.07 | -$2.41-42.6% | -$1.69 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PMN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $9.2M-51.4% | $18.9M+38.9% | $13.6M+96.7% | $6.9M-61.0% | $17.7M |
| Current Assets | $9.2M-51.4% | $18.9M+38.9% | $13.6M+97.3% | $6.9M-61.0% | $17.7M |
| Cash & Equivalents | $6.1M-54.0% | $13.3M+5.5% | $12.6M+114.4% | $5.9M-65.3% | $16.9M |
| Total Liabilities | $10.4M+330.9% | $2.4M-75.4% | $9.9M+19.3% | $8.3M-31.6% | $12.1M |
| Current Liabilities | $10.4M+369.3% | $2.2M-76.3% | $9.3M+45.8% | $6.4M+590.3% | $929K |
| Long-Term Debt | N/A | N/A | $0 | N/A | $3.9M |
| Total Equity | -$1.3M-107.6% | $16.5M+339.3% | $3.8M+378.5% | -$1.3M-123.8% | $5.7M |
| Retained Earnings | -$130.4M-43.8% | -$90.7M+3.0% | -$93.5M-16.5% | -$80.3M-29.0% | -$62.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
PMN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$42.1M | -$28.1M-3.4% | -$27.2M-150.7% | -$10.8M+36.3% | -$17.0M-83.1% | -$9.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $2K-67.2% | $6K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$17.0M-83.0% | -$9.3M |
| Investing Cash Flow | N/A | -$702-1.3% | -$693+48.6% | -$1K+31.9% | -$2K-102.1% | $95K |
| Financing Cash Flow | N/A | $20.9M-24.9% | $27.9M+57.1% | $17.7M+173.3% | $6.5M-74.6% | $25.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PMN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Return on Equity | N/A | 16.9%+368.9pp | -352.0% | N/A | -173.0% |
| Return on Assets | -432.6%-447.2pp | 14.7%+111.7pp | -97.0%+163.8pp | -260.8%-205.7pp | -55.2% |
| Current Ratio | 0.88-7.6x | 8.52+7.1x | 1.46+0.4x | 1.08-18.0x | 19.07 |
| Debt-to-Equity | N/A | 0.15+0.1x | 0.00 | N/A | 0.69 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.88), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Promis Neuroscie Ranks
Frequently Asked Questions
Is Promis Neuroscie profitable?
No, Promis Neuroscie (PMN) reported a net income of -$39.7M in fiscal year 2025.
What is Promis Neuroscie's operating cash flow?
Promis Neuroscie (PMN) recorded an outflow of $28.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Promis Neuroscie's total assets?
Promis Neuroscie (PMN) had $9.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Promis Neuroscie spend on research and development?
Promis Neuroscie (PMN) invested $33.4M in research and development during fiscal year 2025.
What is Promis Neuroscie's current ratio?
Promis Neuroscie (PMN) had a current ratio of 0.88 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Promis Neuroscie's return on assets (ROA)?
Promis Neuroscie (PMN) had a return on assets of -432.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Promis Neuroscie's cash runway?
Based on fiscal year 2025 data, Promis Neuroscie (PMN) had $6.1M in cash against an annual operating cash burn of $28.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Promis Neuroscie's debt-to-equity ratio negative or not reported?
Promis Neuroscie (PMN) has negative shareholder equity of -$1.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Promis Neuroscie's Piotroski F-Score?
Promis Neuroscie (PMN) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Promis Neuroscie's earnings high quality?
Promis Neuroscie (PMN) reported a net loss of $39.7M while operations used $28.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.